Cobra Biologics embarks on £15 m gene therapy manufacturing operations expansion

18 Apr 2017

Capacity increase in response to customer demand for DNA and viral vector production.

Cobra Biologics is to expand operations at its sites in UK and Sweden to meet the increased demand of gene and immunotherapy companies to fast track their portfolios through to in-market supply.

Cobra Biologics embarks on £15 m gene therapy manufacturing operations expansion

Over the next 2 years Cobra will invest up to £15 million (165m SEK) on a phased expansion plan, supporting the company’s R&D expertise in developing rapid and cost effective viral vector and DNA plasmid production platforms. The initial phase, will be in the UK and will extend the company’s viral vector Phase III and commercial manufacturing capabilities to support more customers to rapidly advance their products through clinical trials to in-market supply.  The second phase, in Sweden, will double capacity for High Quality (HQ) DNA plasmid production and characterisation, essential for supporting early clinical phase Adeno-associated virus (AAV) and lentivirus manufacture being used by pioneering CAR T-cell therapy companies targeting acute lymphoblastic leukaemia (ALL) and chronic lymphocytic leukaemia.

The third phase of investment will see the addition of larger clinical and commercial capabilities for GMP DNA production. In total, it is anticipated these investments will create up to 50 new jobs, in addition to the 135 jobs already created in the UK and Sweden since 2011 and will also benefit the wider supply chain companies which provide Cobra with services and facilities.

Peter Coleman, CEO at Cobra Biologics, said: “For almost 20 years Cobra has been manufacturing DNA and viral vectors for its gene therapy customers and we intend to stay at the forefront of this exciting field. Cobra is committed to investing for both present day needs and for the future at this extraordinary time in the history of gene therapy when so many new and potentially life-changing medicines are in the pipe line. Many of these new products have orphan drug status and as a CDMO, we need to respond with a quick and seamless production route to market.”

Greg Hands, UK International Trade Minister welcomed the news: “This new investment by Cobra Biologics is another boost for UK life sciences, creating high-skilled jobs in Keele as the company expands its operations. It comes as global demand for gene therapy manufacturing is surging, helping put the UK at the forefront of developing revolutionary disease therapies and new treatments to be exported around the world.”

Mikael Damberg, Sweden’s Minister for Enterprise and Innovation, also commented: "Sweden is very competitive in life sciences. It is therefore gratifying to be able to welcome the investments announced by Cobra Biologics. Strengthening the life sciences sector’s opportunities to grow, employ and export products and services will pave the way for more skilled jobs in Sweden. It will also contribute to solving societal challenges in health and ageing. Of special interest is the fact that this investment is made in gene therapy, which is an important area for successful treatment of future patients.”

Read More

Related tags

Market News

Related news

Can the industry really claim it's 'business as usual'?

Can the industry really claim it's 'business as usual'?

19 May 2020

ChargePoint Technology's Chief Commercial Officer says "yes" it can.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

19 May 2020

The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Pharmapack expert recommends holistic approach to sustainability

Pharmapack expert recommends holistic approach to sustainability

18 May 2020

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

Read more 
KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

12 May 2020

Company's manufacturing methods and processes reviewed by an independent third-party auditor to ensure the products have the highest-quality ingredients possible.

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

12 May 2020

CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Demand for immunity products to be sustained long-term says SIRIO

Demand for immunity products to be sustained long-term says SIRIO

11 May 2020

Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.

Read more